StockData

ProPhase Labs, Inc. (PRPH) stock

PRPHOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 19, 2026Score 0/30
$0.01−0.00 (-6.16%)

Close on Oct 19, 2026Market cap $119.68KP/E –Yield –

ProPhase Labs free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

ProPhase Labs's free cash flow for the twelve months ending Dec 31, 2025 was -$8.34M. For fiscal 2025 it was -$8.34M. The highest annual figure on record is $24.63M in fiscal 2022.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$8.34M–
FY2024Dec 31, 2024-$18.44M–
FY2023Dec 31, 2023-$13.97M-156.7%
FY2022Dec 31, 2022$24.63M–
FY2021Dec 31, 2021-$17.85M–
FY2020Dec 31, 2020-$4.28M–
FY2019Dec 31, 2019-$1.07M–
FY2018Dec 31, 2018-$2.26M–
FY2017Dec 31, 2017-$3.05M–
FY2016Dec 31, 2016-$1.12M–
FY2015Dec 31, 2015-$4.22M–
FY2014Dec 31, 2014-$3.53M-607.6%
FY2013Dec 31, 2013$695.00K–
FY2012Dec 31, 2012-$6.04M–
FY2011Dec 31, 2011-$2.41M–
FY2010Dec 31, 2010-$3.70M-1662.0%
FY2009Dec 31, 2009$237.00K–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2025Dec 31, 2025-$1.23M–
Q3 FY2025Sep 30, 2025-$3.49M–
Q2 FY2025Jun 30, 2025-$247.00K–
Q1 FY2025Mar 31, 2025-$3.38M–
Q4 FY2024Dec 31, 2024-$3.56M–
Q3 FY2024Sep 30, 2024-$4.04M–
Q2 FY2024Jun 30, 2024-$4.84M–
Q1 FY2024Mar 31, 2024-$6.01M–
Q4 FY2023Dec 31, 2023-$992.00K–
Q3 FY2023Sep 30, 2023-$5.32M-356.1%
Q2 FY2023Jun 30, 2023-$7.62M-283.7%
Q1 FY2023Mar 31, 2023-$41.00K-100.2%
Q4 FY2022Dec 31, 2022-$785.00K–
Q3 FY2022Sep 30, 2022$2.08M–
Q2 FY2022Jun 30, 2022$4.15M+0.4%
Q1 FY2022Mar 31, 2022$19.19M–
Q4 FY2021Dec 31, 2021-$4.62M–
Q3 FY2021Sep 30, 2021-$5.54M–
Q2 FY2021Jun 30, 2021$4.13M-4.8%
Q1 FY2021Mar 31, 2021-$11.82M-7093.5%
Q4 FY2020Dec 31, 2020-$8.24M–
Q3 FY2020Sep 30, 2020-$556.00K–
Q2 FY2020Jun 30, 2020$4.34M–
Q1 FY2020Mar 31, 2020$169.00K-87.5%
Q4 FY2019Dec 31, 2019-$471.00K–
Q3 FY2019Sep 30, 2019-$1.00M–
Q2 FY2019Jun 30, 2019-$952.00K–
Q1 FY2019Mar 31, 2019$1.36M–
Q4 FY2018Dec 31, 2018-$897.00K–
Q3 FY2018Sep 30, 2018-$1.30M-143.9%
Q4 FY2017Dec 31, 2017-$1.73M-1143.4%
Q3 FY2017Sep 30, 2017-$515.00K–
Q2 FY2017Jun 30, 2017-$3.76M–
Q1 FY2017Mar 31, 2017$2.97M–
Q4 FY2016Dec 31, 2016$166.00K–
Q3 FY2016Sep 30, 2016-$774.00K–

More ProPhase Labs figures

See a number that looks wrong?